Cure My Disease

Don't miss your cure!

 Log in / Sign up

Seaweed compounds put to the test against diabetic kidney damage

NCT ID NCT07804641

Disease control Sponsor: Taipei Medical University WanFang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This phase 2 trial tests whether a daily capsule containing fucoidan, fucoxanthin, L-carnitine, and zinc can reduce protein leakage in the urine, a key sign of kidney damage, in people with diabetic kidney disease. About 63 participants will be randomly assigned to receive the supplement or standard care alone for 12 weeks. Researchers will measure changes in urine albumin and kidney function, along with safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of marine-derived supplements: oligo-fucoidan, fucoxanthin, L-carnitine, and zinc yeast, taken as capsules.
What this could lead to
If it works, this supplement combo could offer a new add-on option to help slow kidney damage in people with diabetes.
What could go wrong
This is a small, early-stage trial, and the supplement may not improve kidney function. It is not a replacement for standard diabetes care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

63 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented glycated hemoglobin (HbA1c) \> 6.5% with current use of anti-diabetic medication. * A urine albumin-to-creatinine ratio (UACR) greater than 30 mcg/mg. Exclusion Criteria: * Age younger than 20 years. * Inability to understand or provide written informed consent. * Absence of regular treatment for diabetes mellitus. * Medication non-compliance, defined as completing less than 50% of the prescribed formula (FFL) treatment. * Newly diagnosed glomerulonephritis during the study period. * Loss to follow-up, defined as failure to complete all laboratory tests required for outcome assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease (DKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease (DKD)

Contacts and locations

Locations

  • Wanfang Hospital, Taipei Medical Univeristy

    Taipei, 116, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.